AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

Itepekimab, developed by Sanofi and Regeneron, met its primary endpoint in the AERIFY-1 phase 3 study for COPD, showing a 27% reduction in modera ...

AI will deliver transformative therapies at an exponential scale, addressing the complexities of biology that traditional ...

Qudian Inc. ("Qudian" or "the Company" or "We") , a consumer-oriented technology company in China, today announced its unaudited financial results for the quarter ended . First Quarter 2025 Financial ...